ARDX earnings analysis
What we found in ARDX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ardelyx reported Q1 2026 total product revenue of $93.4 million, beating estimates of $92.4 million and reflecting a 38% year-over-year growth. However, the company reported an EPS loss of $0.15, which was an improvement compared to the estimated loss of $0.14. The guidance for full-year revenue for IBSRELA was reiterated at $410 million to $430 million, indicating a strong outlook despite challenging market conditions.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 38%
- Total revenues increased to $94.5 million from $74.1 million in Q1 2025, driven primarily by a 58% increase in IBSRELA sales.
- Improved EPS Loss
- EPS loss improved to $0.15 from a loss of $0.17 in Q1 2025, outpacing estimates of a $0.14 loss.
- Segment Performance of IBSRELA
- IBSRELA sales surged to $70.1 million from $44.4 million a year ago, reflecting a 58% growth.
- Strong Cash Position
- Cash and cash equivalents decreased to $31.2 million from $68.0 million, while short-term investments increased modestly to $206.9 million.
- Cost of Sales Decrease
- Cost of sales dropped to $4.8 million from $12.3 million, highlighting improved gross margins.
- Maintained Revenue Guidance
- Ardelyx affirmed full-year revenue guidance for IBSRELA at $410 million to $430 million despite potential headwinds.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High R&D Spending
- Research and development expenses rose to $20.2 million from $14.9 million, indicating potential strain on resources.
- Continued Net Loss
- The company recorded a net cash used in operating activities of $32.2 million for the quarter, reflecting ongoing financial challenges.
- Dependence on IBSRELA and XPHOZAH Sales
- Revenue growth heavily reliant on the commercial success of IBSRELA and XPHOZAH amidst competitive pressures.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.15
- Gross margin
- 90.0%
- Operating margin
- -34.4%
- Segment
- IBSRELA
- Segment
- XPHOZAH
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · February 19, 2026
- Ardelyx reported continued top-line growth with quarterly revenue reaching $125.215M in Q4 2025 and FY 2025 revenue of $407.0M (sum of quarterly revenues: $74M, $98M, $110M, $125M). Gross margins expanded (Q4 gross…
- 10-K · February 20, 2025
- Ardelyx reported strong first full-year commercial sales for two tenapanor products in 2024—IBSRELA with approximately $158.3 million and XPHOZAH with approximately $160.9 million—while showing sequential quarterly…
- 10-Q · October 31, 2024
- Ardelyx reported a stronger-than-expected quarter with total revenues of $98,241,000 (vs. $56,391,000 year-ago) driven by product sales of $92,090,000. Gross margin remained high at 84.0% and the company produced…
- 10-Q · August 1, 2024
- Ardelyx reported Q2 product revenue of $73.222M and GAAP EPS of $(0.07). Revenue rose sharply versus Q2 2023 ($22.333M) driven by IBSRELA ($35.445M) and the new XPHOZAH product ($37.146M), resulting in a strong gross…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ARDX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever